**Supplementary Table 1. Comparison of** **hepatic fibro-cirrhosis changes and activity of HBV infection in patients with cirrhosis before and after booster dose****.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Before booster dose** | **After booster dose** | ***p-*value\*** |
| **Liver function index** |  |  |  |
| ALB in g/L, *n* = 22 | 46.6 (44.5–48.3) | 47.1 (44.6–51.2) | 0.194 |
| ALT in U/L, *n* = 22 | 32.0 (19.8–37.5) | 25.0 (21.0–32.3) | 0.286 |
| AST in U/L, *n* = 22 | 26.5 (24.8–34.8) | 28.0 (23.8–32.0) | 0.601 |
| GGT in U/L, *n* = 22 | 34.5 (21.5–43.8) | 31.0 (23.0–37.8) | 0.664 |
| TB in μmol/L, *n* = 16 | 14.7 (11.0–20.0) | 20.5 (11.2–25.3) | 0.234 |
| DB in μmol/L, *n* = 16 | 5.3 (3.9–7.5) | 5.0 (3.9–9.3) | 0.352 |
| **Activity of HBV infection** |  |  |  |
| HBeAg positive | 0 (0/11) | 0 (0/11) | / |
| HBV DNA in IU/mL | 10.0 (10.0–50.0) | 10.0 (10.0–50.0) | 0.852 |
| HBV DNA positive  | 1/17 | 1/17 | 1.000 |
| **Liver parenchymal** |  |  |  |
| Decompensated cirrhosis  | 46.2 (6/13) | 46.2 (6/13) | 1.000 |

Categorical variables are presented as frequencies [% (*n*/*n*)], continuous variables are presented as median (interquartile range). \*Wilcoxon signed-rank test. When the HBV DNA level was lower than the detection limit (20 IU/mL), 10 IU/mL was assigned for calculation. When the HBV DNA level is lower than 100 IU/mL, 50 IU/mL was assigned for calculation. ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DB, direct bilirubin; GGT, gamma-glutamyl transferase; HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid; TB, total bilirubin.